

[Paromomycin](#)

Statut de médicament essentiel

Section:

[6. Anti-infective medicines 6.5. Antiprotozoal medicines 6.5.2. Antileishmaniasis medicines](#)

Codes ATC: [A07AA06](#)

EMLc

Indication

Visceral leishmaniasis Code ICD11: [1F54.0](#)

INN

Paromomycin

Type de médicament

Chemical agent

Groupes d'antibiotiques

[WATCH](#)

Type de liste

Liste de base

Formulations

Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)

Historique des statuts LME

Ajouté pour la première fois en 2007 ([TRS 946](#))

Modifié en 2007 ([TRS 950](#))

Sexe

Tous

Âge

Aussi recommandé pour les enfants

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets.](#)

Wikipédia

[Paromomycin](#)

DrugBank

[Paromomycin](#)

Résumé des preuves et recommandation du comité d'experts



Paromomycin was considered at the 15th Expert Committee meeting in March 2007, where paromomycin solution for intramuscular (IM) injection was added to the Model List. The Expert Committee concluded that paramomycin was effective in terms of effect on standard endpoints, such as initial and final cure, for the treatment of visceral leishmaniasis in children and adults. Paromomycin is licensed in India, and was granted orphan drug designation by the US Food and Drug Administration (FDA) in March 2005 and the European Medicines Agency (EMA) in April 2005. The EMLc Subcommittee endorsed the listing of paromomycin IM injection on the first EMLc.